For example, approximately 50% of adult melanomas carry an oncogenic BRAFV600 mutation and approximately 20% carry an oncogenic NRAS mutation16, prompting use of selective inhibitors which target the mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase-AKT pathways17, 18, 19. This evidence concerns the gene NRAS and melanoma.